Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Sustained asthma control and remission in real-world patients with severe eosinophilic asthma receiving benralizumab: XALOC-2.

The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Same author

Beta<sub>2</sub>-agonist and anti-inflammatory combination therapy for asthma rescue: a paradigm shift in asthma care.

Frontiers in medicine·2026
Same author

Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial.

Diagnostics (Basel, Switzerland)·2026
Same author

Educational Intervention on Environmentally Responsible Inhaler Prescribing Among French General Practitioners: Pilot Pre-Post Study.

JMIR formative research·2026
Same author

Complex interplay between disease and aerobic exercise training on vascular function in an exacerbated emphysema rat model.

Journal of applied physiology (Bethesda, Md. : 1985)·2026
Same author

Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis.

Regional anesthesia and pain medicine·2026

相关实验视频

Updated: May 11, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.8K

严重喘中的真实世界生物使用模式,2015-2021年:CLEAR研究

Trung N Tran1, Stephanie Chen1, Benjamin Emmanuel1

  • 1Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.

Pragmatic and observational research
|March 24, 2025
PubMed
概括

切换或停止严重喘的生物治疗与更糟糕的结果有关. 与改变或停止治疗相比,继续初始生物治疗与更好的临床结果和更少的恶化有关.

关键词:
伊斯兰国家安全组织 (ISAR)生物学的生物学.有效性 有效性.现实世界的真实世界.严重的喘 严重的喘

更多相关视频

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

29.9K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.4K

相关实验视频

Last Updated: May 11, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.8K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

29.9K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.4K

科学领域:

  • 肺部病理学 肺部病理学
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 针对免疫球蛋白E,白内素 (IL) - 4/IL-13,或IL-5通路的生物药物用于严重的喘.
  • 低于最佳的患者反应可能会导致治疗修改,需要对现实世界的数据进行分析.

研究的目的:

  • 评估严重喘患者生物使用的现实世界模式.
  • 评估与继续,切换或停止生物治疗相关的临床结果.

主要方法:

  • 一项多中心的观察性研究 (CLEAR) 涉及来自国际严重喘登记处的23个国家的1859名成年人.
  • 患者根据他们的生物治疗轨迹 (继续,切换,停止) 在开始6个月内被分类.
  • 结果在12个月后使用倾向分数加权的多变量回归模型来评估结果.

主要成果:

  • 60.0%的人继续使用,25.5%的人转换,14.5%的人停止生物治疗.
  • 切换或停止与更高的年度喘恶化率和不受控制的喘有关.
  • 与继续治疗的患者相比,切换患者的口服皮质类固醇使用,住院和急诊室访问量增加.

结论:

  • 在严重喘中切换或停止生物治疗与较差的临床结果有关.
  • 持续的初始生物治疗似乎与更有利的长期结果有关.